Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

Background. Omeprazole is mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. Pabeprazole, on the other hand, is mainly metabolized to thioether-rabeprazole via a non-enzymatic pathway and partially metabolized to demethylated-rabeprazole by CYP2C19 in liver. CYP2C19 status may affect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2001-11, Vol.33 (8), p.671-675
Hauptverfasser:	Dojo, M., Azuma, T., Saito, T., Ohtani, M., Muramatsu, A., Kuriyama, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Pyridinylmethylsulfinylbenzimidazoles Adult Amoxicillin - therapeutic use Aryl Hydrocarbon Hydroxylases Benzimidazoles - therapeutic use Clarithromycin - therapeutic use CYP2C19 Cytochrome P-450 CYP2C19 Cytochrome P-450 Enzyme System - genetics Drug Therapy, Combination Female Gastritis - drug therapy Gastritis - microbiology Genotype Helicobacter Infections - drug therapy Helicobacter Infections - genetics Helicobacter pylori Helicobacter pylori infection Humans Japan Male Middle Aged Mixed Function Oxygenases - genetics omeprazole Omeprazole - therapeutic use Polymorphism, Genetic Prospective Studies Proton-Translocating ATPases - therapeutic use Rabeprazole Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!